Tag: Marketwatch

Aug 03
Oil logs modest gain ahead of OPEC+ meeting

William Watts is MarketWatch’s senior markets writer. Based in New York, Watts writes about stocks, bonds, currencies and commodities, including oil. He also writes about global macro issues and trading strategies. Before moving to New York, he reported for MarketWatch from Frankfurt, London and Washington, D.C. Source: Marketwatch

Aug 03
AMTD Digital issues ‘thank you note’ to investors as stock trades about 23,650% above IPO price

The U.S.-listed shares of Hong Kong-based investment holding company AMTD IDEA Group AMTD, +236.54% skyrocketed 312.5% and subsidiary AMTD Digital Inc. HKD, +126.28%, a Hong-Kong-based digital solutions applications developer, rocketed 149.6% in very volatile afternoon trading Tuesday, enough to make them the two best performers listed on the New York Stock Exchange. AMTD IDEA shares […]

Aug 03
White House says China shouldn’t turn Pelosi’s Taiwan visit into a crisis

There’s no reason for Beijing to turn House Speaker Nancy Pelosi’s Taiwan visit, which is consistent with long-standing U.S. policy, into some sort of crisis or use it as a pretext to increase aggressiveness and military activity in or around the Taiwan Strait, said John Kirby, a spokesman for the White House’s National Security Council. […]

Aug 03
Herbalife stock gains after earnings beat expectations, as company says ‘underlying business trends stabilized’

A previous version of this report misstated the FactSet consensus estimate for Herbalife’s second-quarter adjusted earnings per share. Shares of Herbalife Nutrition Ltd. HLF, -1.38% were up 11% in after-hours trading Tuesday after the company easily topped expectations with its latest results. The company logged second-quarter net income of $86.5 million, or 88 cents a […]

Aug 03
Alteryx soars on second-quarter sales growth

Alteryx Inc. AYX, +4.23% shares surged 12.3% in extended trading on Tuesday, lifted by the data analytics software company’s second-quarter sales growth. The company’s stock closed Tuesday’s session up 4.2% at $50.57. Alteryx’s second-quarter revenue was $180.6 million, an increase of 50%, compared to revenue of $120.1 million in the year-ago quarter. “Alteryx delivered an […]

Aug 02
Financial markets may see three-month string of 8.8% inflation readings starting next week, adding up to `bad news’

The financial market’s most knowledgeable inflation traders are expecting a string of roughly 8.8% annual headline U.S. consumer-price readings over the next three months, starting with the Aug. 10 release of July’s data. While such readings would be below June’s 9.1% reading and support the theory that inflation may have peaked at an almost 41-year […]

Aug 02
Dow ends 400 points lower Tuesday after historic Taiwan visit defies China

U.S. stocks closed lower for a second straight day on Tuesday, after U.S. House Speaker Nancy Pelosi defied China with a historic visit to Taiwan. The blue chip Dow Jones Industrial Average [djia] shed about 401 points, or 1.2%, ending near 32,396, while the S&P 500 index SPX, -0.67% closed 0.7% lower and the Nasdaq […]

Aug 02
Gold prices score 5th straight day of wins Tuesday with U.S.-China tensions in focus

Gold prices end higher Tuesday, climbing for a fifth straight day, after U.S. House Speaker Nancy Pelosi landed in Taiwan, sparking vows of retaliation from Beijing. December gold GCZ22, -0.26% GC00, -0.26% rose 0.1% to settle at $1,789.70 an ounce, with the most-active contract ending higher in the past five sessions. Investors also continued to […]

Aug 02
Why China-Taiwan tensions moved to the forefront of financial market worries

It’s an island off the coast of China, with a land area comparable to Maryland and Delaware combined. Its population is about 1 million higher than that of Florida. Often overlooked in world headlines, Taiwan is grabbing the financial market’s attention as the biggest macro risk of the day, prompting many traders and investors to […]

Aug 02
Eliem’s stock slides 20% after saying it will discontinue development of pain treatment

Shares of Eliem Therapeutics Inc. ELYM, -12.58% tumbled 20.0% in premarket trading on Tuesday after the company said it will discontinue development of its treatment for lumbosacral radicular pain after a Phase 2a clinical trial didn’t yield strong enough results. Eliem said it has enough capital to fund the development of other therapies and its […]